Global Blood Therapeutics Investor Webcast from the American Society of Hematology Annual Meeting
Mon, Dec 5, 2016 12:15 PM PST
During the live and archived event, Global Blood Therapeutics will highlight data presented at the ASH meeting from GBT’s ongoing Phase 1/2 GBT440-001 trial including results of dosing GBT440 at 900 mg per day in SCD patients for up to 6 months, and the metabolism of GBT440 in healthy subjects, as well as the methodology utilized to develop the Patient Reported Outcome (PRO) tool that will be used in the HOPE (Hemoglobin Oxygen Affinity Modulation to Inhibit HbS PolymErization) Study.
Ted W. Love, M.D.
Chief Executive Officer of GBT
Jo Howard MRCP., FRCPath
Honorary Reader in Haemoglobin Opathy, Guy’s and St Thomas’ NHS Foundation Trust
Wally R. Smith, M.D.
Virginia Commonwealth University Medical Center